Trends in the eradication rates of Helicobacter pylori infection for eleven years
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Jai Hoon | - |
dc.contributor.author | Baik, Gwang Ho | - |
dc.contributor.author | Sohn, Kyoung Min | - |
dc.contributor.author | Kim, Dae Yong | - |
dc.contributor.author | Kim, Yeon Soo | - |
dc.contributor.author | Suk, Ki Tae | - |
dc.contributor.author | Kim, Jin Bong | - |
dc.contributor.author | Kim, Dong Joon | - |
dc.contributor.author | Kim, Jin Bae | - |
dc.contributor.author | Shin, Woon Geon | - |
dc.contributor.author | Kim, Hak Yang | - |
dc.contributor.author | Baik, Il Hyun | - |
dc.contributor.author | Jang, Hyun Joo | - |
dc.date.accessioned | 2022-07-16T12:08:25Z | - |
dc.date.available | 2022-07-16T12:08:25Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2012-12 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/163873 | - |
dc.description.abstract | AIM: To evaluate the trends in the eradication rate of Helicobacter pylori (H. pylori) over the past 11 years in a single center. METHODS: This retrospective study covered the period from January 2000 to December 2010. We evaluated 5746 patients diagnosed with gastric ulcers (GU), duodenal ulcers (DU), GU + DU, or nonpeptic ulcers associated with an H. pylori infection. We treated them annually with the 2 wk standard first-line triple regimen, proton pump inhibitor (PPI) + amoxicilin + clarithromycin (PAC; PPI, clarithromycin 500 mg, and amoxicillin 1 g, all twice a day). The follow-up test was performed at least 4 wk after the completion of the 2 wk standard H. pylori eradication using the PAC regimen. We also assessed the eradication rates of 1 wk second-line therapy with a quadruple standard regimen (PPI b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d. and tetracycline 500 mg q.i.d.) after the failure of the first-line therapy. Statistical analysis was performed with 95%CI for the differences in the annual eradication rates. RESULTS: A total of 5746 patients [2333 males (58.8%), 1636 females (41.2%); mean age of males vs females 51.31 ± 13.1 years vs 52.76 ± 13.6 years, P < 0.05, total mean age 51.9 ± 13.3 years (mean ± SD)] were investigated. Among these patients, 1674 patients were excluded: 35 patients refused treatment; 18 patients ceased H. pylori eradication due to side effects; 1211 patients had inappropriate indications for H. pylori eradication, having undergone stomach cancer operation or chemotherapy; and 410 patients did not undergo the follow-up. We also excluded 103 patients who wanted to stop eradication treatment after only 1 wk due to poor compliance or the side effects mentioned above. Finally, we evaluated the annual eradication success rates in a total of 3969 patients who received 2 wk first-line PAC therapy. The endoscopic and clinical findings in patients who received the 2 wk PAC were as follows: gastric ulcer in 855 (21.5%); duodenal ulcer in 878 (22.1%); gastric and duodenal ulcer in 124 (3.1%), erosive, atrophic gastritis and functional dyspepsia in 2055 (51.8%); and other findings (e.g., MALToma, patients who wanted to receive the therapy even though they had no abnormal endoscopic finding) in 57 (0.5%). The overall eradication rate of the 2 wk standard firstline triple regimen was 86.5%. The annual eradication rates from 2000 to 2010 were 86.7%, 85.4%, 86.5%, 83.3%, 89.9%, 90.5%, 88.4%, 84.5%, 89.1%, 85.8%, and 88.3%, sequentially (P = 0.06). No definite evidence of a significant change in the eradication rate was seen during the past eleven years. The eradication rates of second-line therapy were 88.9%, 82.4%, 85%, 83.9%, 77.3%, 85.7%, 84.4%, 87.3%, 83.3%, 88.9%, and 84% (P = 0.77). The overall eradication rate of 1 wk quadruple second-line therapy was 84.7%. There was no significant difference in the eradication rate according to the H. pylori associated diseases. CONCLUSION: This study showed that there was no trend change in the H. pylori eradication rate over the most recent 11 years in our institution. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | W J G PRESS | - |
dc.title | Trends in the eradication rates of Helicobacter pylori infection for eleven years | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Jai Hoon | - |
dc.identifier.doi | 10.3748/wjg.v18.i45.6628 | - |
dc.identifier.scopusid | 2-s2.0-84873904009 | - |
dc.identifier.wosid | 000312476300016 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.18, no.45, pp.6628 - 6634 | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 18 | - |
dc.citation.number | 45 | - |
dc.citation.startPage | 6628 | - |
dc.citation.endPage | 6634 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | MAASTRICHT-III CONSENSUS | - |
dc.subject.keywordPlus | PROTON PUMP INHIBITOR | - |
dc.subject.keywordPlus | ANTIBIOTIC-RESISTANCE | - |
dc.subject.keywordPlus | TRIPLE THERAPIES | - |
dc.subject.keywordPlus | UNITED-STATES | - |
dc.subject.keywordPlus | CLARITHROMYCIN | - |
dc.subject.keywordPlus | AMOXICILLIN | - |
dc.subject.keywordPlus | OMEPRAZOLE | - |
dc.subject.keywordPlus | METRONIDAZOLE | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.subject.keywordAuthor | Eradication | - |
dc.subject.keywordAuthor | Proton pump inhibitor | - |
dc.subject.keywordAuthor | Therapy | - |
dc.subject.keywordAuthor | Clarithromycin | - |
dc.identifier.url | https://www.wjgnet.com/1007-9327/full/v18/i45/6628.htm | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.